Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2004 April;95(2) > Minerva Medica 2004 April;95(2):93-104

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Medica 2004 April;95(2):93-104

Copyright © 2004 EDIZIONI MINERVA MEDICA

language: English

Gene therapy for type 1 diabetes. New approaches

Morral N.


PDF


Type 1 or insulin-dependent diabetes mellitus is a metabolic disease that results from the destruction of pancreatic b-cells. Most patients receive subcutaneous insulin injections to reduce blood glucose levels. However, strict glucose control by multiple insulin injections is associated with an increased risk of hypoglycemia and weight gain, while a less strict glucose control is insufficient to prevent chronic complications such as nephropathy, neuropathy and retinopathy. Gene therapy holds a tremendous therapeutic potential to improve glycemic control by restoring endogenous insulin production. This review focuses on recent advances directed at producing insulin in an ectopic tissue as well as inducing pancreatic b-cell neogenesis. The strategies include constitutive and promoter-regulated insulin expression in the liver; increasing hepatic glucose oxidation; insulin production from intestinal cells; and islet cell neogenesis in liver and pancreas.

top of page